1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Fax: (718) 920-1123
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia
Article first published online: 27 JUL 2004
DOI: 10.1002/cncr.20494
Copyright © 2004 American Cancer Society
Additional Information
How to Cite
Karbasian-Esfahani, M., Wiernik, P. H., Novik, Y., Paietta, E. and Dutcher, J. P. (2004), Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia. Cancer, 101: 1414–1419. doi: 10.1002/cncr.20494
Publication History
- Issue published online: 1 SEP 2004
- Article first published online: 27 JUL 2004
- Manuscript Accepted: 10 JUN 2004
- Manuscript Revised: 4 JUN 2004
- Manuscript Received: 1 APR 2004
- Abstract
- Article
- References
- Cited By
Keywords:
- idarubicin;
- cytosine arabinoside;
- acute lymphocytic leukemia;
- recurrent and refractory acute lymphocytic leukemia
The response rate of the regimen of idarubicin and cytosine arabinoside in patients with recurrent or refractory acute lymphocytic leukemia compared favorably with other regimens with acceptable toxicity.
Abstract
BACKGROUND
Drug resistance and early disease recurrence were major contributing factors in the limited survival of patients with acute lymphocytic leukemia (ALL). New chemotherapeutic agents and drug combinations were employed in refractory patients to overcome drug resistance.
METHODS
The current study evaluated the efficacy of a regimen comprising intravenous bolus injections of idarubicin, 12 mg/m2 daily × 3, and a continuous 7-day infusion of cytosine arabinoside (ara-C), 100 mg/m2 daily, in adults with refractory or recurrent ALL. Twenty patients aged 14–75 years were treated.
RESULTS
Six patients (30%) achieved complete remission (CR), 5 (25%) had a partial response (PR), and 9 (45%) did not respond. Recovery of blood counts occurred at a median of 20 days. One patient who achieved CR and one who achieved PR survived 1.5 and 2 years, respectively, after receiving this treatment. The median response and overall survival periods were 2.75 and 6.3 months, respectively. There was no relation between remission duration and previous chemotherapy. Neither leukocyte count at study entry nor patient karyotype was associated with attainment of CR. All patients experienced profound myelosuppression. Gastrointestinal toxicity was mild to moderate, with the exception of one case of World Health Organization Grade 3 mucositis.
CONCLUSIONS
The regimen of idarubicin and ara-C achieved a 55% overall response rate in patients with recurrent or refractory ALL. This response rate compared favorably with other regimens and was achieved with acceptable toxicity. Response duration was disappointing, however. Cancer 2004. © 2004 American Cancer Society.